:quality(85):upscale()/2023/09/18/918/n/1922398/a1136b676508baddc752f5.20098216_.jpg)
:quality(85):upscale()/2025/10/09/670/n/1922283/00b944c868e7cf4f7b79b3.95741067_.jpg)
:quality(85):upscale()/2025/10/15/765/n/1922398/29c37a6e68efd84bb02f35.49541188_.jpg)
:quality(85):upscale()/2025/09/09/891/n/1922283/7222624268c08ccba1c9a3.01436482_.png)
EU legislators strike pharmaceutical deal
BRUSSELS — EU lawmakers have clinched a long-awaited agreement on the bloc’s overhaul of its two decades-old pharmaceutical rules — one of the EU’s biggest health files.
The revamp is designed to restore Europe’s competitive edge and give companies more certainty that the EU remains an attractive market, while also pushing for more equal access to medicines across member countries.
The deal between the Parliament and the Council was struck at 5 a.m. on Thursday, more than two years after the Commission tabled the proposal, which consists of directive and regulation, in spring 2023.
It marks a major victory for the Danish presidency, which pledged to wrap up the file before the end of the year, and for Health Commissioner Olivér Várhelyi, who has pushed to seal the reform amid growing geopolitical uncertainty.
